Cart
Hospital Acquired Urinary Tract Infection Market by Product (Microbial Testing Instruments, Reagents and Consumables, Infection Prevention, and Surveillance Software), by Application (Disease Testing and Drug-resistance Testing), by Technology (Phenotypic Methods and Genotypic Methods), by Disease (Hospital acquired Pneumonia, Bloodstream infections, Surgical site infections, Gastrointestinal Infections, and Urinary Tract infections (UTI), and Others), and by End User (Hospitals and Intensive Care Units (ICUs), Ambulatory Surgical and Diagnostic Centers, Nursing Homes and Maternity Centers, and Others) - Global Opportunity Analysis and Industry and Forecast, 2019-2026
|
LI_183686
|
Pages: NA
|
Jul 2019 |
1244 Views
|
|
|
|
Author(s) :
NA
|
Tables: NA
|
Charts: NA
|
Formats*:
|
|
Hospital acquired urinary tract infections are caused by patients urethral catheters or invasive manipulation in the urogenital tract, which allows microbes to enter into the bladder and encourages proliferation by providing a sustainable environment. Hospital acquired UTIs are accountable for over 50% of infections. An array of tests can uncover type of infection and pathogen associated with the infection to efficiently treat the infected area.
Increase in prevalence of hospital acquired UTIs and technological advancement in testing devices drive the market. Moreover, favorable reimbursement scenario and focused disease management boost the market growth. However, strict regulatory policies and introduction of new testing devices into the market restrict the growth. Surge in preference over substitute products such as anti-infection catheters impedes the market growth.
The global hospital acquired urinary tract infection market is segmented on the basis of product, application, technology, disease, end user, and geography. On the basis of product, the market is divided into microbial testing instruments, reagents and consumables, infection prevention, and surveillance software. The microbial testing instruments are further divided into automated microbial identification systems, polymerase chain reaction (PCR) instruments, mass spectrometers, microarrays, polystainers, flow cytometers, and others. By application, the market is classified into disease testing, drug-resistance testing. On the basis of technology, the market is divided into phenotypic methods (phage-based assays, colorimetric methods, and nitrate reductase assay) and genotypic methods (DNA sequencing, solid-phase hybridization techniques, polymerase chain reaction techniques, microarrays). By diseases, the market is categorized into hospital acquired pneumonia, bloodstream infections, surgical site infections, gastrointestinal infections, urinary tract infections (UTI), and others. By end user, the market is segmented into hospitals and intensive care units (ICUs), ambulatory surgical and diagnostic centers, nursing homes and maternity centers, and others. By geography, it is analyzed across North America, Europe, Asia Pacific, and LAMEA.
Comprehensive competitive analysis and profiles of major market players such as Advanced Sterilization Products (Division Ethicon Us, LLC), Becton, Dickinson and Company, Steris Corporation, Getinge Group, Kimberly-Clark Corporation, Cantel Medical, Biomerieux SA, Belimed AG, 3M Company, Sterigenics International LLC., Synergy Health, and PLC are provided in this report.
Key Benefits
- The study provides an in-depth analysis of the market along with current trends and future estimations to elucidate the imminent investment pockets.
- Extensive analysis of the market is conducted by following key product positioning and monitoring the top competitors within the market framework
- It offers a quantitative analysis from 2017 to 2023 to enable the stakeholders to capitalize on the prevailing market opportunities.
- Comprehensive analysis of all geographical regions is provided to determine the prevailing opportunities.
- Key players are profiled and their strategies are analyzed thoroughly to understand the competitive outlook of the global market.
Hospital Acquired Urinary Tract Infection Market Key Segments:
By Product
- Microbial Testing Instruments
- Automated Microbial Identification Systems
- Polymerase Chain Reaction (PCR) Instruments
- Mass Spectrometers
- Microarrays
- Polystainers
- Flow Cytometers
- Others
- Reagents and Consumables
- Infection Prevention and Surveillance Software
By Application
- Disease Testing
- Drug-resistance Testing
By Technology
- Phenotypic Methods
- Phage-Based Assays
- Colorimetric Methods
- Nitrate Reductase Assay
- Genotypic Methods
- DNA Sequencing
- Solid-Phase Hybridization Techniques
- Polymerase Chain Reaction Techniques
- Microarrays
By Disease
- Hospital acquired Pneumonia
- Bloodstream infections
- Surgical site infections
- Gastrointestinal Infections
- Urinary Tract infections (UTI)
- Others
By End User
- Hospitals and Intensive Care Units (ICUs)
- Ambulatory Surgical and Diagnostic Centers
- Nursing Homes and Maternity Centers
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Taiwan
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Turkey
- Saudi Arabia
- South Africa
- Rest of LAMEA
CHAPTER 1 INTRODUCTION
1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools & models
CHAPTER 2 EXECUTIVE SUMMARY
2.1. CXO PERSPECTIVE
CHAPTER 3 MARKET OVERVIEW
3.1. MARKET DEFINITION AND SCOPE
3.2. KEY FINDINGS
3.2.1. Top investment pockets
3.2.2. Top winning strategies
3.3. MARKET SHARE ANALYSIS, 2016
3.4. PORTER’S FIVE FORCES ANALYSIS
3.4.1. MARKET DYNAMICS
3.4.2. Drivers
3.4.3. Restraints
3.4.4. Opportunities
CHAPTER 4 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY PRODUCT
4.1. OVERVIEW
4.1.1. Market size and forecast
4.2. MICROBIAL TESTING INSTRUMENTS
4.2.1. Key market trends
4.2.2. Growth factors and opportunities
4.2.3. Market size and forecast
4.2.4. Automated Microbial Identification Systems
4.2.5. Polymerase Chain Reaction (PCR) Instruments
4.2.6. Mass Spectrometers
4.2.7. Microarrays
4.2.8. Polystainers
4.2.9. Flow Cytometers
4.2.10. Others
4.3. REAGENTS AND CONSUMABLES
4.3.1. Key market trends
4.3.2. Growth factors and opportunities
4.3.3. Market size and forecast
4.4. INFECTION PREVENTION AND SURVEILLANCE SOFTWARE
4.4.1. Key market trends
4.4.2. Growth factors and opportunities
4.4.3. Market size and forecast
CHAPTER 5 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY APPLICATION
5.1. OVERVIEW
5.1.1. Market size and forecast
5.2. DISEASE TESTING
5.2.1. Market size and forecast
5.3. DRUG-RESISTANCE TESTING
5.3.1. Market size and forecast
CHAPTER 6 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY TECHNOLOGY
6.1. OVERVIEW
6.1.1. Market size and forecast
6.2. PHENOTYPIC METHODS
6.2.1. Market size and forecast
6.2.2. Phage-based Assays
6.2.3. Colorimetric Methods
6.2.4. Nitrate Reductase Assay
6.3. GENOTYPIC METHODS
6.3.1. Market size and forecast
6.3.2. DNA Sequencing
6.3.3. Solid-phase Hybridization Techniques
6.3.4. Polymerase Chain Reaction Techniques
6.3.5. Microarrays
CHAPTER 7 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY DISEASE
7.1. OVERVIEW
7.1.1. Market size and forecast
7.2. HOSPITAL ACQUIRED PNEUMONIA
7.2.1. Market size and forecast
7.3. BLOODSTREAM INFECTIONS
7.3.1. Market size and forecast
7.4. SURGICAL SITE INFECTIONS
7.4.1. Market size and forecast
7.5. GASTROINTESTINAL INFECTIONS
7.5.1. Market size and forecast
7.6. URINARY TRACT INFECTIONS (UTI)
7.6.1. Market size and forecast
7.7. OTHERS
7.7.1. Market size and forecast
CHAPTER 8 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY END USER
8.1. OVERVIEW
8.1.1. Market size and forecast
8.2. HOSPITALS AND INTENSIVE CARE UNITS (ICUS)
8.2.1. Market size and forecast
8.3. AMBULATORY SURGICAL AND DIAGNOSTIC CENTERS
8.3.1. Market size and forecast
8.4. NURSING HOMES AND MATERNITY CENTERS
8.4.1. Market size and forecast
8.5. OTHERS
8.5.1. Market size and forecast
CHAPTER 9 HOSPITAL ACQUIRED URINARY TRACT INFECTION MARKET, BY GEOGRAPHY
9.1. OVERVIEW
9.2. NORTH AMERICA
9.2.1. Key market trends
9.2.2. Key growth factors and opportunities
9.2.3. Market size and forecast
9.2.3.1. U.S. market size and forecast
9.2.3.2. Canada market size and forecast
9.2.3.3. Mexico market size and forecast
9.3. EUROPE
9.3.1. Key market trends
9.3.2. Key growth factors and opportunities
9.3.3. Market size and forecast
9.3.3.1. Germany market size and forecast
9.3.3.2. France market size and forecast
9.3.3.3. UK market size and forecast
9.3.3.4. Italy market size and forecast
9.3.3.5. Spain market size and forecast
9.3.3.6. Rest of Europe market size and forecast
9.4. ASIA-PACIFIC
9.4.1. Key market trends
9.4.2. Key growth factors and opportunities
9.4.3. Market size and forecast
9.4.3.1. Japan market size and forecast
9.4.3.2. China market size and forecast
9.4.3.3. Australia market size and forecast
9.4.3.4. India market size and forecast
9.4.3.5. South Korea market size and forecast
9.4.3.6. Taiwan market size and forecast
9.4.3.7. Rest of Asia-Pacific market size and forecast
9.5. LAMEA
9.5.1. Key market trends
9.5.2. Key growth factors and opportunities
9.5.3. Market size and forecast
9.5.3.1. Brazil market size and forecast
9.5.3.2. Turkey market size and forecast
9.5.3.3. Saudi Arabia market size and forecast
9.5.3.4. South Africa market size and forecast
9.5.3.5. Rest of LAMEA market size and forecast
CHAPTER 10 COMPANY PROFILES
10.1. ADVANCED STERILIZATION PRODUCTS (DIVISION ETHICON US, LLC)
10.1.1. Operating business segments
10.1.2. Business performance
10.1.3. Key strategic moves and developments
10.2. BECTON, DICKINSON AND COMPANY
10.2.1. Operating business segments
10.2.2. Business performance
10.2.3. Key strategic moves and developments
10.3. STERIS CORPORATION
10.3.1. Operating business segments
10.3.2. Business performance
10.3.3. Key strategic moves and developments
10.4. GETINGE GROUP
10.4.1. Operating business segments
10.4.2. Business performance
10.4.3. Key strategic moves and developments
10.5. KIMBERLY-CLARK CORPORATION
10.5.1. Operating business segments
10.5.2. Business performance
10.5.3. Key strategic moves and developments
10.6. CANTEL MEDICAL, BIOMERIEUX SA
10.6.1. Operating business segments
10.6.2. Business performance
10.6.3. Key strategic moves and developments
10.7. BELIMED AG
10.7.1. Operating business segments
10.7.2. Business performance
10.7.3. Key strategic moves and developments
10.8. 3M COMPANY
10.8.1. Operating business segments
10.8.2. Business performance
10.8.3. Key strategic moves and developments
10.9. STERIGENICS INTERNATIONAL LLC
10.9.1. Operating business segments
10.9.2. Business performance
10.9.3. Key strategic moves and developments
10.10 SYNERGY HEALTH, AND PLC
10.10.1 Operating business segments
10.10.2 Business performance
10.10.3 Key strategic moves and developments
We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:
- Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
- Technologically sophisticated and reliable insights through well audited and veracious research methodology
- Sovereign research proceeds that present a tangible depiction of marketplace
With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.
Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, web-casts and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast
Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develops analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth and forecasts
Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:
- Chief executives and VPs of leading corporations specific to industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)
Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.
REQUEST TOC/SAMPLE
Purchase Full Report of
Hospital Acquired Urinary Tract Infection Market- Global Opportunity Analysis and Industry and Forecast, 2019-2026
- Online Only
-
$3456$3110 - Online cloud access only
- Restricted print, copy, paste & download
- Read only
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Data Pack
-
$3840$3456 - Restricted to one authorized user
- One print only
- Available in Excel
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Single User
-
$5370$4833 - Restricted to one authorized user
- One print only
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
- Five Users
-
$6450$5805 - Limited to five authorized users
- Print upto five copies
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
-
Enterprise
License/PDF -
$8995$8096 - Unlimited within company/enterprise
- Available in Excel & PDF
- 20% free customization (Pre-Sale)
- Free quarterly industry update
- Free report update (Within 180 days)
- Subscription model sign in
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
TARGETED MARKET VIEW
Targeted market view to provide pertinent information and save time of readers
Get fresh content delivered
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Buy Full Version
"Hospital Acquired Urinary Tract Infection Market"
Purchase Enquiry